2025
The Interplay Between Respiratory Syncytial Virus and Asthma Inception: Insights Gained From the COVID‐19 Pandemic
Amram T, Duek O, Golan‐Tripto I, Goldbart A, Greenberg D, Hazan G. The Interplay Between Respiratory Syncytial Virus and Asthma Inception: Insights Gained From the COVID‐19 Pandemic. Pediatric Pulmonology 2025, 60: e27474. PMID: 39760467, PMCID: PMC11748096, DOI: 10.1002/ppul.27474.Peer-Reviewed Original ResearchConceptsRespiratory syncytial virusYears of ageSyncytial virusRespiratory syncytial virus bronchiolitisRespiratory syncytial virus infectionRespiratory syncytial virus exposureRSV-induced inflammationRespiratory syncytial virus activityMultivariate logistic regressionAirway changesAsthma inceptionRetrospective studyAsthma surrogateIncreased riskLogistic regressionAsthmaCause of asthmaCOVID-19 pandemicHealthcare organizationsPredispositionIncreased rateChildrenCOVID-19AgeVirus
2024
Does Eosinophil Heterogeneity Translate into Functional Diversity? A Review of the Evolving Paradigm of Eosinophil Heterogeneity in Asthma
Wilson G, Gautam S, Chupp G. Does Eosinophil Heterogeneity Translate into Functional Diversity? A Review of the Evolving Paradigm of Eosinophil Heterogeneity in Asthma. Biomedicines 2024, 12: 2011. PMID: 39335525, PMCID: PMC11428232, DOI: 10.3390/biomedicines12092011.Peer-Reviewed Original ResearchType 2 inflammatory diseasesTreatment of patientsEosinophil subtypesEosinophilic phenotypeFunctional diversityClinical therapyEosinophil heterogeneityEosinophil subpopulationsBiological agentsEosinophilsPhenotypic changesFunctional roleAsthmaOverview of evidenceDiseaseSubpopulationsMepolizumabTherapyPatientsSubtypesReviewNeighborhood Socioeconomic Context Predicts Pediatric Asthma Exacerbation
Kranjac A, Kain Z, Ehwerhemuepha L, Weiss M, Jenkins B. Neighborhood Socioeconomic Context Predicts Pediatric Asthma Exacerbation. Clinical Pediatrics 2024, 64: 310-318. PMID: 39044420, DOI: 10.1177/00099228241262997.Peer-Reviewed Original ResearchNon-Hispanic Black residentsAsthma exacerbationsElectronic medical record dataLevels of ambient air pollutionNeighborhood-level factorsAssociated with greater oddsMedical record dataAmbient air pollutionIndividual-level factorsPlace-based initiativesProportion of female-headed householdsAsthma managementNeighborhood characteristicsGreater oddsAsthma controlUncontrolled asthmaBlack residentsFemale-headed householdsRecord dataInadequate disease controlMultilevel modeling techniquesPediatric patientsResidential characteristicsAsthmaIndividual levelThe role of positive affect in asthma control and symptom severity in adolescents
Jenkins B, Martin L, Halterman J, Moskowitz J, Glynn L, Tirakitsoontorn P, Kamath S, Kain Z. The role of positive affect in asthma control and symptom severity in adolescents. Journal Of Adolescence 2024, 96: 1673-1683. PMID: 39015022, DOI: 10.1002/jad.12373.Peer-Reviewed Original ResearchPositive affectSymptom severityAsthma symptom severityArousal componentAsthma controlEffect of positive affectPsychological triggersHigher levels of stressSurveyed 4 timesLevels of stressModerate to severe asthmaAffectAsthma triggersSubscale componentsAdolescentsPatient stressSymptomsWellbeingAsthmaSeverityAssociationSevere asthmaHigher levelsArousalBeyond Air Pollution: Addressing Multifactorial Contributors to Asthma Disparities in Black and Latinx Populations.
Ou J, Yuan Y, Fu X, Sun Y. Beyond Air Pollution: Addressing Multifactorial Contributors to Asthma Disparities in Black and Latinx Populations. American Journal Of Respiratory And Critical Care Medicine 2024, 210: 696-697. PMID: 38935619, PMCID: PMC11389579, DOI: 10.1164/rccm.202405-1031le.Peer-Reviewed Original ResearchAdoption and implementation of maintenance and reliever therapy for adults with moderate-to-severe asthma
Zaeh S, Zimmerman Z, Eakin M, Chupp G. Adoption and implementation of maintenance and reliever therapy for adults with moderate-to-severe asthma. Annals Of Allergy Asthma & Immunology 2024, 133: 318-324. PMID: 38897404, PMCID: PMC11344662, DOI: 10.1016/j.anai.2024.06.011.Peer-Reviewed Original ResearchAcademic health care systemHealth care systemClinician characteristicsCare systemCross-sectional studySevere asthmaModerate to severe asthmaRetrospective cross-sectional studyClinician dataLong-acting bronchodilatorsAsthma guidelinesAsthma managementPrescribed to patientsSubspecialty cliniciansShort-acting bronchodilatorsReliever therapyAsthma exacerbationsChart reviewPatient demographicsOlder patientsCliniciansAllergy practiceAsthma groupAsthmaPatientsWhat Are Some Strategies to Enhance Asthma Education in My Practice?
Tolomeo C. What Are Some Strategies to Enhance Asthma Education in My Practice? 2024, 199-202. DOI: 10.1201/9781003523611-46.Peer-Reviewed Original ResearchWhat Education Should Be Provided to All Parents of Children With Asthma to Help With Day-to-Day Management?
Tolomeo C. What Education Should Be Provided to All Parents of Children With Asthma to Help With Day-to-Day Management? 2024, 203-206. DOI: 10.1201/9781003523611-47.Peer-Reviewed Original ResearchAsthma educationAsthma self-management education programSelf-management education programWritten Asthma Action PlanAsthma action planNational Asthma Education and Prevention Program's Expert Panel Report 3Expert Panel Report 3Self-monitoring symptomsManagement of asthmaParents of childrenEducational interventionAsthma medicationsEPR-3Medical carePediatric settingAsthma controlDay-to-day managementReport 3Education programsNAEPPGuidelines stateAction planAsthmaDevice techniqueEducationHow Can I Deal With Asthma Symptoms Over the Telephone Safely and Efficiently?
Tolomeo C. How Can I Deal With Asthma Symptoms Over the Telephone Safely and Efficiently? 2024, 141-144. DOI: 10.1201/9781003523611-33.Peer-Reviewed Original ResearchHow Is Asthma Diagnosed in Infancy and Childhood?
Bazzy-Asaad A. How Is Asthma Diagnosed in Infancy and Childhood? 2024, 103-105. DOI: 10.1201/9781003523611-25.Peer-Reviewed Original ResearchWhat Are the Most Current Asthma Guidelines From the National Institutes of Health and What Do I Need to Know About Them?
Bazzy-Asaad A. What Are the Most Current Asthma Guidelines From the National Institutes of Health and What Do I Need to Know About Them? 2024, 113-116. DOI: 10.1201/9781003523611-27.Peer-Reviewed Original ResearchAsthma control in the United States Relationships between short-acting β2-agonist and systemic corticosteroid use
Chupp G, Murphy K, Gandhi H, Gilbert I, Bleecker E. Asthma control in the United States Relationships between short-acting β2-agonist and systemic corticosteroid use. Annals Of Allergy Asthma & Immunology 2024, 133: 302-309. PMID: 38740134, DOI: 10.1016/j.anai.2024.05.003.Peer-Reviewed Original ResearchMild to moderate diseaseSystemic corticosteroidsMild-to-moderateSevere asthmaUncontrolled asthmaSystemic corticosteroid exposureSystemic corticosteroid useAsthma control assessmentCorticosteroid useExacerbation historyRetrospective analysisSABA useUS patientsPrescription fillsPatientsLongitudinal accessAsthma controlDisease severityAsthmaDiseaseExacerbationPearson correlation coefficientHigh symptom burdenPatient severitySymptom burdenAssociation of lichen planus with asthma and allergic rhinitis in the All of Us Research Program: a cross-sectional study
Richmond R, Murphy M, Edemobi P, Vesely M, Cohen J. Association of lichen planus with asthma and allergic rhinitis in the All of Us Research Program: a cross-sectional study. Clinical And Experimental Dermatology 2024, 49: 1067-1069. PMID: 38589773, PMCID: PMC11340807, DOI: 10.1093/ced/llae101.Peer-Reviewed Original Research
2023
EFFICACY OF TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA WITH COMORBID GASTROESOPHAGEAL REFLUX DISEASE: A POOLED ANALYSIS OF THE PATHWAY AND NAVIGATOR STUDIES
MOORE W, LUGOGO N, CHUPP G, MARTIN N, AMBROSE C, COOK W, ACKERT J. EFFICACY OF TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA WITH COMORBID GASTROESOPHAGEAL REFLUX DISEASE: A POOLED ANALYSIS OF THE PATHWAY AND NAVIGATOR STUDIES. CHEST Journal 2023, 164: a4-a7. DOI: 10.1016/j.chest.2023.07.073.Peer-Reviewed Original ResearchLONG-TERM EFFICACY OF TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA BY BASELINE BODY MASS INDEX
CHUPP G, LUGOGO N, WECHSLER M, LAWSON K, LINDSLEY A, SPAHN J, AMBROSE C. LONG-TERM EFFICACY OF TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA BY BASELINE BODY MASS INDEX. CHEST Journal 2023, 164: a9-a14. DOI: 10.1016/j.chest.2023.07.075.Peer-Reviewed Original ResearchA SMART Shift in Pediatric Asthma
Banasiak N, Keil Heinonen S, Filippelli A. A SMART Shift in Pediatric Asthma. The Journal For Nurse Practitioners 2023, 19: 104641. DOI: 10.1016/j.nurpra.2023.104641.Peer-Reviewed Original ResearchReliever therapyPatients 4 yearsOral corticosteroid useSevere persistent asthmaSingle maintenanceQuality of lifeNational AsthmaSingle inhalerAsthma exacerbationsCorticosteroid usePersistent asthmaPediatric asthmaClinical practiceAsthmaPrevention programsExpert panelTherapyNew recommendationsRelevant evidenceExacerbationInhalerEfficacy of Tezepelumab in Patients With Severe, Uncontrolled Asthma by Sex: Results From the Phase 3 Navigator Study
Kraft M, Chupp G, Reeh K, Lindsley A, Cook B, Hunter G, Ambrose C. Efficacy of Tezepelumab in Patients With Severe, Uncontrolled Asthma by Sex: Results From the Phase 3 Navigator Study. 2023, a4751-a4751. DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a4751.Peer-Reviewed Original ResearchClinical Remission Achievement in Severe Asthma Following Mepolizumab Treatment: Results From the REALITI-A Study at 2 Years
Brusselle G, Lougheed M, Canonica G, Munoz-Esquerre M, Heaney L, Price R, Howarth P, Raimondi A, Gardiner F, Chupp G, Welte T. Clinical Remission Achievement in Severe Asthma Following Mepolizumab Treatment: Results From the REALITI-A Study at 2 Years. 2023, a5985-a5985. DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5985.Peer-Reviewed Original ResearchSarcoidosis and Airway Disease After Immune Checkpoint Inhibitor Therapy: Case Study and Review of the Literature
Soto F, Torre-Sada L, Mott F, Kim S, Nurieva R, Nagarajan P, Guo M, Shannon V, Faiz S, Casal R, Altan M, Lin J, Sheshadri A. Sarcoidosis and Airway Disease After Immune Checkpoint Inhibitor Therapy: Case Study and Review of the Literature. Journal Of Immunotherapy And Precision Oncology 2023, 6: 111-116. PMID: 37214206, PMCID: PMC10195014, DOI: 10.36401/jipo-22-30.Peer-Reviewed Original ResearchImmune checkpoint inhibitor therapyCheckpoint inhibitor therapyInhibitor therapyPulmonary toxicityEosinophilic asthmaAirway diseaseImmune related adverse eventsPD-1 inhibitor pembrolizumabSevere eosinophilic asthmaRelated adverse eventsICI therapyInhibitor pembrolizumabPD-1Benign courseTreatment cessationFatal complicationCase reportAdverse eventsSarcoidosisTherapyPneumonitisAirwayPatientsToxicityAsthmaReal-World Impact of Mepolizumab on the Oral Corticosteroid Freedom Component of Clinical Remission in Severe Eosinophilic Asthma: International, Prospective REALITI-A Study
Chupp G, Heaney L, Price R, Brusselle G, Gardiner F, Raimondi A, Chaudhuri R, Howarth P. Real-World Impact of Mepolizumab on the Oral Corticosteroid Freedom Component of Clinical Remission in Severe Eosinophilic Asthma: International, Prospective REALITI-A Study. Journal Of Allergy And Clinical Immunology 2023, 151: ab20. DOI: 10.1016/j.jaci.2022.12.066.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply